Detection of T cells secreting type 1 and type 2 cytokines in the peripheral blood of patients with oral lichen planus

Kalogerakou F, Albanidou-Farmaki E, Markopoulos A K, Antoniades D Z

Department of Oral Medicine and Maxillofacial Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece

Abstract

Objective: The purpose of this study was to detect and enumerate T cells secreting type 1 and 2 cytokines in the peripheral blood of patients with oral lichen planus (OLP) and in healthy controls.

Subjects and Methods: The study group consisted of 80 OLP patients and 80 healthy individuals. Cytokine secreting T cells were detected using ELISPOT assay.

Results: There was a statistically significant decrease (p<0.05) in the number of IFN-γ and IL-12 secreting cells in the peripheral blood of patients with OLP compared to the controls. No statistical difference was observed in the number of IL-2 and TNF-a secreting cells between OLP patients and controls (p>0.05). Also there was no significant difference in the numbers of IFN-γ, IL-12, IL-2 and TNF-a secreting cells between reticular and erosive forms of OLP (p>0.05).

As regards type 2 cytokines, the number of IL-5 and IL-10 secreting cells was significantly decreased in OLP patients compared to the healthy control group (p<0.05). No statistical difference was observed in the number of IL-6 secreting cells between OLP patients and control group (p>0.05). Similarly, no statistical difference was observed in the number of IL-4 secreting cells between OLP patients and controls (p>0.05). No significant difference was also found in the numbers of IL-4, IL-5, IL-10 and IL-6 secreting cells between reticular and erosive OLP group.

Conclusion: These data suggest decreased type 1 and type 2 cytokine production (except IL-4) in OLP patients.

Key words: T helper cells, type 1 cytokine, type 2 cytokines, peripheral blood, oral lichen planus

Correspondence: Albanidou-Farmaki E, Department of Oral Medicine and Maxillofacial Pathology, School of Dentistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece, fax: +302310 99-9455, e-mail: elfarmaki@yahoo.gr
pathologic diagnosis were the presence of hyperkeratosis, degenerative alterations of the basal cells as well as inflammatory infiltrates in the lamina propria consisting mainly of lymphocytes and histiocytes. Peripheral blood samples were obtained from healthy volunteers and OLP patients by venepuncture in the active stage of the disease. The whole study was conducted according to Helsinki declaration.

Isolation of T cells

T cells were purified by density centrifugation (2000 rpm for 30 min, at 5°C) on Ficoll, were isolated and centrifuged three more times at 2500 rpm, for 10 min, at 5°C with RPMI-1640 and were supplemented with 10% heat inactivated Fetal Bovine Serum, 1% Heps Buffer 10Mm, 1% penicillin 1U/ml, 1% streptomycin 1μg/ml and 1% L-glutamine 2Mm. All reagents were purchased by Biochrom KG, Berlin, Germany. T cells were finally resuspended in RPMI-1640 medium at a concentration of 1 x 10^6 cells/ml for IL-2 assay, 1x 10^5 cells/ml for IL-12 assay, 2 x 10^5 cells/ml for TNF-a assay and 5 x 10^4 cells/ml for IFN-γ assay.

Cytokine ELISPOT (Elisa spots) assay.

Commercially available ELISPOT kits were used to measure IL-2, IL-12, TNF-a, IFN-γ, IL-4, IL-5, IL-6, and IL-10 producing cells (Diaclone Research, Besançon, France). Each kit contained concentrated solutions of capture and detection antibodies, concentrated solution of streptavidin conjugated alkaline-phosphatase and BCIP/NBT substrate. Assays were performed according to the protocol that was included in each ELISPOT kit. The 96-well PVDF-bottomed-well plates (Millipore Multiscreen, France) were coated with100 μl/well of monoclonal anti-cytokine detection antibody into phosphate buffer saline (PBS) (Sigma, St Louis, USA). For each plate 100 μl of capture antibody into 10 ml of PBS was used. The antibody was kept into the plates overnight at 4°C.

Plates were then washed with PBS and consequent dilutions of cells suspension, starting with 5-10 x 10^4 cells/ml (for IL-2 assay), 1-10 x 10^5 cells/ml (for IL-12 assay), 2-4 x 10^4 cells/ml (for TNF-a assay) and 2-5 x 10^4 cells/ml (for IFN-γ assay) in RPMI-1640 medium and were incubated on cytokine-coated plates at 37°C for 15-20 hours in a humidified environment with 5% CO2. Plates were washed three times with PBS- 0.1%, Tween 20 and were overlaid with 100 μl/well of biotinylated detection anticytokine antibody into PBS, containing 1% BSA (for each plate we used 100 μl of reconstituted detection antibody into 10 mL of PBS containing 1% BSA) and were incubated for 1 hour 30 min at 37°C. Plates were then washed again three times with PBS-0.1%, Tween 20 and treated with 1:1000 dilution of streptavidin-conjugated alkaline phosphatase into PBS-1% BSA for 1 hour at 37° C and were washed three times with PBS-0.1% Tween 20. The cytokine secreted by single cells was visualized by the addition of BCIP/NBT in wells. The colorimetric reaction was halted after 20 minutes by washing with distilled water and the number of spots in the wells, each representing one cytokine-producing cell, was evaluated using a light microscope. The numbers of cytokine producing cells were counted under a stereo microscope and were expressed as cells/well.

Statistical analysis

Statistical differences between the numbers of cytokine producing cells of OLP patients and control group were determined by two tailed t-test. Statistical differences between the numbers of cytokine producing cells of reticular type of OLP patients group and erosive type of OLP patients group were determined by two tailed t-test. Results were expressed as mean ± S.E.M for each group.

Results

The numbers of IFN-γ and IL-12 producing cells were significantly lower (p<0.05) in OLP patients (68.5 ± 13 IFN-γ producing cells/well and 54.9 ± 10 IL-12 producing cells/well) than in control group (123.6 ± 14 IFN-γ producing cells/ml and 89 ± 13 IL-12 producing cells/well, respectively). No statistical difference (p>0.05) was observed in the numbers of IL-2 and TNF-a producing cells between OLP patients (76.7 ± 19 IL-2 producing

<table>
<thead>
<tr>
<th></th>
<th>OLP group</th>
<th>Control group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ producing cells</td>
<td>68.5 ± 13</td>
<td>123.6 ± 14</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>IL-12 producing cells</td>
<td>54.9 ± 10</td>
<td>89± 13</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>IL-2 producing cells</td>
<td>76.7± 19</td>
<td>88 ± 19</td>
<td>p&gt; 0.05</td>
</tr>
<tr>
<td>TNF-α producing cells</td>
<td>1450 ± 140</td>
<td>1840 ± 160</td>
<td>p&gt; 0.05</td>
</tr>
</tbody>
</table>

Table 1: Elispot results. Numbers of T cells secreting type 1 cytokines in the peripheral blood of OLP patients and control group. Results are expressed as the number of cytokine producing cells/ well (mean±S.E.M.).
cells/well and 1450 ± 140 TNF-α producing cells/well) and controls (88 ± 19 IL-2 producing cells/well and 1840 ± 160 TNF-α producing cells/well) (Table 1).

As for IFN-γ, IL-12, IL-2 and TNF-α producing cells in reticular and erosive OLP patients, no significant difference was observed between the two groups (p>0.05) (Table 2).

As for Type 2 cytokines, the numbers of IL-5 and IL-10 producing cells were found to be significantly lower (p<0.05) in OLP group (48.2 ± 4 IL-5 producing cells/well and 730 ± 100 IL-10 producing cells/well) compared to control group (88.2 ± 9 IL-5 producing cells/well and 1930 ± 290 IL-10 producing cells/well, respectively). No statistical difference (p>0.05) was observed in the number of IL-6 producing cells between OLP patients and controls (661 ± 95 vs. 804 ± 85 IL-6 producing cells/well, respectively). Similarly, no statistical difference (p>0.05) was observed in the number of IL-4 producing cells between OLP patients and controls (117 ± 22 vs. 73.1 ± 11 IL-4 producing cells/well, respectively) (Table 3).

As for IL-4, IL-5, IL-10 and IL-6 producing cells in reticular and erosive OLP patients, no significant difference (p>0.05) was observed between the two groups (Table 4).

### Discussion

In this study, we detected and compared the IL-2, IFN-γ, IL-12, TNF-α, IL-4, IL-5, IL-10 and IL-6 producing cells in the peripheral blood of OLP patients and healthy controls. ELISPOT assays were used to detect cytokine producing cells from peripheral blood in both groups. The results have shown a decrease of IFN-γ, IL-12, IL-5, IL-10 and IL-6 producing cells in patients with OLP.

Cytokines play an important role in the immune system as they mediate and regulate immune and inflammatory reactions. Type 1 cytokines primarily promote cell mediated immunity. In our study, the numbers of IFN-γ and IL-12 producing cells in peripheral blood were found to be significantly decreased in OLP group compared to healthy controls (p<0.05), indicating a suppressed cell mediated immune response in OLP patients (Th1 response). IFN-γ inhibits the differentiation and effector functions of type 2 cytokines secreting cells and can lead to a dominant Th1 response. The antigen presenting cell (APC)-derived cytokine IL-12, strongly drives the differentiation of type 1 cytokine secreting cells, in vivo and in vitro, partly through its potent induction of IFN-γ production.

### Table 2

ELISpot results. Type 1 cytokine-producing cells from peripheral blood of patients with reticular and erosive OLP. Results are expressed as the number of cytokine producing cells/well (mean ± S.E.M.).

<table>
<thead>
<tr>
<th></th>
<th>Reticular OLP group</th>
<th>Erosive OLP group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ producing cells</td>
<td>97 ± 32</td>
<td>57 ± 25</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>IL-12 producing cells</td>
<td>58 ± 17</td>
<td>50 ± 12</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>IL-2 producing cells</td>
<td>55 ± 13</td>
<td>81.7 ± 22</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>TNF-α producing cells</td>
<td>1270 ± 200</td>
<td>1550 ± 220</td>
<td>p&gt;0.05</td>
</tr>
</tbody>
</table>

### Table 3

Elispot results. Numbers of T cells secreting type 2 cytokines in the peripheral blood of OLP patients and control group. Results are expressed as the number of cytokine producing cells/well (mean±S.E.M.).

<table>
<thead>
<tr>
<th></th>
<th>OLP group</th>
<th>Control group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-5 producing cells</td>
<td>48.2 ± 4</td>
<td>88.2 ± 9</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>IL-10 producing cells</td>
<td>730 ± 100</td>
<td>1930 ± 290</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>IL-4 producing cells</td>
<td>117 ± 22</td>
<td>73.1 ± 11</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>IL-6 producing cells</td>
<td>661 ± 95</td>
<td>804 ± 85</td>
<td>p&gt;0.05</td>
</tr>
</tbody>
</table>
No statistical difference was observed in the numbers of IL-2 and TNF-α producing cells in the peripheral blood of patients with OLP compared with the control group. However, a slight, not statistically important decrease in the numbers of IL-2 and TNF-α producing cells was observed in the peripheral blood of patients with OLP. IL-2 is produced by T cells and acts as a growth factor for antigen-stimulated T lymphocytes. It is also responsible for T cell clonal expansion after antigen recognition. IL-2 also regulates IFN-γ production by T cells. Moreover, TNF-α is produced from macrophages, T cells, and other types of cells when stimulated with IL-2, GM-CSF, or TNF-α itself. A possible explanation for the observed decreased number of type 1 cytokine producing cells in the peripheral blood of OLP patients could be a deficiency at the level of co-operation between antigen-presenting cells (APCs) and T lymphocytes via MHC class II antigens and antigen/T cell receptor (TCR).

The decreased number of cytokine producing cells in peripheral blood in OLP group indicates an impairment of their effector functions. Although ineffective in peripheral blood lymphocytes of OLP patients have been described, the etiologic significance remains unclear. Yamamoto et al. have suggested that OLP patient’s lymphocytes and neutrophil functions are impaired and that cellular immunosuppression is a pathologic characteristic of OLP. Previous studies demonstrated reduced spontaneous lymphocyte proliferation and lower IFN-γ secretion in OLP patients compared with controls. Their results suggest a defect in OLP T cell activation localized between IL-2 receptor ligand binding and IFN-γ secretion.

Reduced mitogen-stimulated lymphocyte proliferation has also been reported but not in all OLP patients. Furthermore, IL-2, IFN-γ and TNF-α production from PHA stimulated peripheral blood lymphocytes was found to be decreased in OLP patients compared to the control group. Administration of phytohaemagglutinin (PHA) in low doses, restored OLP T cell proliferative response and cytokine production to normal levels, suggesting that the defect could not be attributed to numerical differences or deletion of T cell subsets but rather to T cell hyporesponsiveness.

Measurements in the serum of OLP patients in some studies revealed that IL-2 levels were very low, while TNF-α and IFN-γ levels were found slightly increased. In our study, type 1 cytokine expression was tested with Elispot assay exclusively in peripheral blood.

While OLP pathogenesis remains unclear, anti-keratinocyte auto-cytotoxic T cell clones in OLP lesions suggest a role for autoimmunity and cell-mediated cytotoxicity in OLP. Khan et al. suggest that the development of a type 1 cytokine immune response in OLP lesions may promote CD8+ cytotoxic T cell activity in OLP. Thus, OLP may be considered as a hyper-reactive, immunostimulatory condition.

Recent studies identified IFN-γ expression by T cells adjacent to basal keratinocytes in oral LP and IFN-γ production and secretion by oral LP lesional T cells in vitro. More IL-2 was generated by tissue infiltrated mononuclear cells in OLP lesions (TIMC) compared to TIMC in the gingiva and peripheral blood.

In contrary, the results in our study have shown decreased numbers of type 1 cytokine producing cells in peripheral blood of OLP patients. It could be hypothesized that tissue-infiltrated mononuclear cells are stimulated in situ and produce cytokines, that OLP is a localized autoimmune disease and that the inflammatory condition of OLP is determined by local cytokine network. The suppressed function of T helper cells in OLP may indicate an inability to respond to the immune reaction following antigen recognition in OLP lesion. Even though the proinflammatory cytokines – i.e. IFN-γ and TNF-α play an important role in tissue destruction in autoimmune diseases, several data suggest that they can also activate homeostatic mechanisms to suppress inflammation. Previous studies have suggested that a

**Table 4: ELISPOT results. Type 2 cytokine-producing cells from the peripheral blood of patients with reticular and erosive OLP. Results are expressed as the number of cytokine producing cells/ well (mean ± S.E.M.).**

<table>
<thead>
<tr>
<th></th>
<th>Reticular OLP group</th>
<th>Erosive OLP group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-5 producing cells</td>
<td>51.4 ± 7.2</td>
<td>45.8 ± 5.3</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>IL-10 producing cells</td>
<td>529 ± 140</td>
<td>878 ± 160</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>IL-4 producing cells</td>
<td>141 ± 37</td>
<td>114 ± 46</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>IL-6 producing cells</td>
<td>610 ± 140</td>
<td>712 ± 150</td>
<td>p &gt; 0.05</td>
</tr>
</tbody>
</table>
defect in immunoregulation—specifically involving suppressor mechanisms—may facilitate cellular autoreactivity in OLP.

Regarding the role of type 2 cytokines, IL-10 is an inhibitory cytokine, produced by T cells, macrophages/microphages, B cells, eosinophils, mast cells and keratinocytes. The major physiologic roles of IL-10 include limiting inflammation, preventing an overwhelming immune response and supporting the humoral immune response. Previous studies suggest a crucial immunosuppressive role for IL-10, as the specific cytokine induces the differentiation of a subset of regulatory CD4+ T cells (Tr1) that produce IL-10 and some IL-5. IL-5 is a cytokine primarily involved in the pathogenesis of atopic diseases and acts as a link between T cell activation and eosinophilic inflammation. In our study, the number of IL-5-producing cells was significantly decreased in OLP patients (p<0.05).

Furthermore, anti-keratinocytes auto-cytotoxic T cell clones in OLP lesions suggest a role for autoimmunity and cell-mediated cytotoxicity in OLP.

Therefore, the decreased number of IL-10 producing cells in peripheral blood in OLP patients may indicate an inability of the immune system to inhibit the cytotoxic process following the antigen recognition in OLP lesions. Previous studies have shown defective peripheral immune suppressor function in OLP and have suggested that a defect in immunoregulation—specifically involving suppressor mechanisms—may facilitate cellular autoreactivity in OLP.

In addition, the number of IL-6-producing cells was also found to be decreased in OLP patients, but non-statistically important (p>0.05). IL-6 may be produced by various activated cells, including monocytes, macrophages, T cells and B lymphocytes. IL-6 plays an important role in acute phase response, in B cell differentiation and stimulation, in T cell growth and differentiation. Previous studies have observed elevated IL-6 serum levels in OLP patients which reflect the chronic inflammatory nature of OLP. This could be due to local and systemic production of IL-6 by many cell types. Moreover, Sun et al suggested that peripheral blood mononuclear cells and endothelial cells may be the systemic cellular sources of IL-6. Even though IL-6 plays an important role in acute phase reactions, endogenous IL-6 plays a crucial anti-inflammatory role in both local and systemic acute inflammatory responses by controlling the level of proinflammatory type 1 cytokine. Thus, the decreased number of IL-6-producing cells in peripheral blood in OLP patients may indicate suppression of peripheral immune response in OLP patients that finally allows the OLP inflammatory process to proceed.

Even if the results in our study have shown decreased number of producing cells producing the type 2 cytokines IL-10, IL-5 and IL-6 in peripheral blood of OLP patients, the number of IL-4 producing cells was found increased in OLP patients, although there was no statistical significance (p>0.05). IL-4 is the principal cytokine that promotes the development of type 2 cytokines secreting cells and stimulates B cell Ig heavy chain class switching to the IgE isotype. Few studies in OLP sera have shown a slight increase in serum IL-4 levels or nearly the same levels as the control group. Although IL-4 is not strictly an anti-inflammatory cytokine, in some cases it can regulate autoimmunity by antagonizing the development of type 1 responses.

The lack of difference in the number of cytokine type 1 and type 2 producing cells (IFN-γ, IL-12, TNF-α and IL-10 IL-5, IL-4 and IL-6 respectively) suggests that the same deficiency of the immune system can be expressed with different clinical picture.

The decreased numbers of IFN-γ, IL-12, IL-2 and TNF-α producing cells in OLP indicates suppressed function and down regulation of type 1 immune response. Whether this alteration of the immune condition in OLP patients participates to the pathogenic pathway of the disease, remains to be determined. As for type 2 cytokines, the decreased number of the IL-10 producing cells in OLP could not be able to inhibit the activation and expansion of autoreactive lymphocytes and might allows cytotoxic reaction to proceed in OLP lesion.

References

14. Mosemann T, Sad S. The expanding universe of T cell subsets: TH1, TH2 and more. Immunology Today 1996; 17: 138-146


41. Hagiwara E, Abbasi F, Mor G, Ishigatsubo Y, Kliman D. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-A in human peripheral blood. Cytokine 1995; 7: 815-822.


